Identification of novel therapeutic targets by genome analysis in breast cancer
- Prosjektnummer
- 2011049
- Ansvarlig person
- Kristine Kleivi Sahlberg
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 6. Treatment Evaluation
High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.
PLoS One 2013;8(10):e77232. Epub 2013 okt 23
PMID: 24194875 - Inngår i doktorgradsavhandlingen
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.
In press in Genome Medicine
Identifying alternative compounds for HER2 positive breast cancer cells by drug screening
AACR, Washington D.C., USA, 4th-10th April 2013. Poster presentation.
Identifying alternative compounds for HER2 positive breast cancer cells by drug screening
Global Academic Program Conference, Oslo, Norway, May 2012
Identifying alternative compounds for HER2 positive breast cancer cells by drug screening
22nd Annual Biocity Symposium, "Personal Genomics - from technologies to applications", Turku, Finland, August 2012
Identifying alternative compounds for HER2 positive breast cancer cells by drug screening
Personalized Cancer Care, Holmenkollen, Norway, September 2012
Inhibition of HER2 positive breast cancer cells by drug screening
Oral presentation at ECCO in Stockholm October 2011
The search for therapeutic targets in breast cancer by genome analyses
- Disputert:
- desember 2014
- Hovedveileder:
- Kristine Kleivi Sahlberg
- Sandra Johanna Nyberg Doktorgradsstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport